Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Sodium Ferric Gluconate Complex→

Sodium Ferric Gluconate Complex Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
34089-81-1
Molecular formula
Not a single fixed molecule
FDA structural formula
[NaFe2O3(C6H11O7)(C12H22O11)5]n, n ≈ 200
Apparent molecular weight
289,000–440,000 Da (gel chromatography)

Identification source: FDA Ferrlecit prescribing information describes this as a stable macromolecular complex, gives the structural formula shown, and reports the apparent molecular-weight range by gel chromatography. The range reflects the complex rather than a single small molecule.

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Sodium Ferric Gluconate Complex Environmental Risk Assessment (ERA) (the Sodium Ferric Gluconate Complex ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.